Find recruiting clinical trials for colorectal cancer in the UK — colon, rectal, and bowel cancer subtypes. See your treatment pathway and where trials fit in.
Free to use · Live data from ClinicalTrials.gov · Updated hourly
See where clinical trials fit into your treatment journey
Initial systemic treatment for metastatic disease
Standard: FOLFOX or FOLFIRI + Bevacizumab or Cetuximab (RAS wild-type)
After progression on 1st-line therapy
Standard: Switch chemotherapy backbone + targeted therapy
After multiple lines — clinical trials are especially important
Standard: Regorafenib, TAS-102, or clinical trial
RAS and BRAF mutations affect which targeted therapies will work. Anti-EGFR therapies (cetuximab, panitumumab) only work in RAS wild-type tumours. BRAF V600E mutations indicate poorer prognosis and specific treatment approaches.
Microsatellite instability (MSI-H) or deficient mismatch repair (dMMR) occurs in about 5% of metastatic CRC. These patients respond exceptionally well to immunotherapy (pembrolizumab).
About 3-5% of CRC tumours overexpress HER2. Emerging evidence supports HER2-targeted combinations (trastuzumab + pertuzumab or trastuzumab + lapatinib) in this subgroup.
Loading trials from ClinicalTrials.gov...